Okano Miho, Hara Takeo, Hata Tomoki, Tanizaki Keiko, Takayama Osamu, Kim Yongkook, Imamoto Haruhiko, Hasegawa Junichi
Dept. of Surgery, Kaizuka City Hospital.
Gan To Kagaku Ryoho. 2023 Mar;50(3):404-406.
The patient was 40s male, who underwent laparoscopic low anterior resection for his upper rectal cancer with final pathology results of tub2, pT3(SS), no lymph metastasis and fStage Ⅱ. He was followed up without adjuvant chemotherapy. Half a year after surgery, tumor marker was elevated and CT scan revealed multiple liver metastases. He was treated with oxaliplatin, irinotecan, Leucovorin and 5-fluorouracil(FOLFOXIRI)plus bevacizumab because of RAS mutant type. In the third courses, he has pain in the lower extremities and was diagnosed with acute lower extremity arterial occlusion. Subsequently, chemotherapy was resumed with the exception of bevacizumab, in combination with DOAC, which resulted in tumor shrinkage and allowed resection of the liver metastases.
该患者为40多岁男性,因上段直肠癌接受腹腔镜低位前切除术,最终病理结果为tub2、pT3(SS),无淋巴结转移,fStageⅡ期。他未接受辅助化疗进行随访。术后半年,肿瘤标志物升高,CT扫描显示多发肝转移。由于RAS突变型,他接受了奥沙利铂、伊立替康、亚叶酸钙和5-氟尿嘧啶(FOLFOXIRI)联合贝伐单抗治疗。在第三个疗程中,他出现下肢疼痛,被诊断为急性下肢动脉闭塞。随后,除贝伐单抗外,恢复化疗,并联合直接口服抗凝药(DOAC),这导致肿瘤缩小,并允许切除肝转移灶。